OncoCyte (OCX) Competitors $2.65 -0.07 (-2.57%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$2.64 -0.02 (-0.57%) As of 02/21/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends OCX vs. SLDB, PBYI, BMEA, CHRS, MCRB, TELO, TIL, KYTX, TSVT, and BDTXShould you be buying OncoCyte stock or one of its competitors? The main competitors of OncoCyte include Solid Biosciences (SLDB), Puma Biotechnology (PBYI), Biomea Fusion (BMEA), Coherus BioSciences (CHRS), Seres Therapeutics (MCRB), Telomir Pharmaceuticals (TELO), Instil Bio (TIL), Kyverna Therapeutics (KYTX), 2seventy bio (TSVT), and Black Diamond Therapeutics (BDTX). These companies are all part of the "pharmaceutical products" industry. OncoCyte vs. Solid Biosciences Puma Biotechnology Biomea Fusion Coherus BioSciences Seres Therapeutics Telomir Pharmaceuticals Instil Bio Kyverna Therapeutics 2seventy bio Black Diamond Therapeutics OncoCyte (NASDAQ:OCX) and Solid Biosciences (NASDAQ:SLDB) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, media sentiment, analyst recommendations, community ranking, profitability, risk, valuation, institutional ownership and dividends. Do institutionals & insiders hold more shares of OCX or SLDB? 55.4% of OncoCyte shares are owned by institutional investors. Comparatively, 81.5% of Solid Biosciences shares are owned by institutional investors. 1.6% of OncoCyte shares are owned by company insiders. Comparatively, 13.6% of Solid Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has more volatility & risk, OCX or SLDB? OncoCyte has a beta of 0.9, suggesting that its stock price is 10% less volatile than the S&P 500. Comparatively, Solid Biosciences has a beta of 2.01, suggesting that its stock price is 101% more volatile than the S&P 500. Does the media refer more to OCX or SLDB? In the previous week, Solid Biosciences had 23 more articles in the media than OncoCyte. MarketBeat recorded 24 mentions for Solid Biosciences and 1 mentions for OncoCyte. Solid Biosciences' average media sentiment score of 0.91 beat OncoCyte's score of 0.00 indicating that Solid Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OncoCyte 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Solid Biosciences 10 Very Positive mention(s) 4 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is OCX or SLDB more profitable? Solid Biosciences has a net margin of 0.00% compared to OncoCyte's net margin of -6,122.29%. Solid Biosciences' return on equity of -58.75% beat OncoCyte's return on equity.Company Net Margins Return on Equity Return on Assets OncoCyte-6,122.29% -269.32% -59.71% Solid Biosciences N/A -58.75%-47.84% Which has stronger earnings & valuation, OCX or SLDB? OncoCyte has higher earnings, but lower revenue than Solid Biosciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOncoCyte$1.50M30.83-$27.78MN/AN/ASolid Biosciences$8.09M28.99-$96.01M-$3.04-1.90 Do analysts rate OCX or SLDB? OncoCyte currently has a consensus target price of $4.42, indicating a potential upside of 66.67%. Solid Biosciences has a consensus target price of $15.40, indicating a potential upside of 166.44%. Given Solid Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Solid Biosciences is more favorable than OncoCyte.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OncoCyte 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67Solid Biosciences 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 4 Strong Buy rating(s) 3.31 Does the MarketBeat Community favor OCX or SLDB? Solid Biosciences received 263 more outperform votes than OncoCyte when rated by MarketBeat users. Likewise, 69.04% of users gave Solid Biosciences an outperform vote while only 8.33% of users gave OncoCyte an outperform vote. CompanyUnderperformOutperformOncoCyteOutperform Votes98.33%Underperform Votes9991.67% Solid BiosciencesOutperform Votes27269.04% Underperform Votes12230.96% SummarySolid Biosciences beats OncoCyte on 15 of the 17 factors compared between the two stocks. Get OncoCyte News Delivered to You Automatically Sign up to receive the latest news and ratings for OCX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OCX vs. The Competition Export to ExcelMetricOncoCyteDiagnostic substances IndustryMedical SectorNASDAQ ExchangeMarket Cap$47.47M$2.30B$5.84B$9.14BDividend YieldN/A0.75%4.75%3.85%P/E RatioN/A5.0426.0419.11Price / Sales30.8362.84447.4676.36Price / CashN/A15.7538.0134.83Price / Book1.073.287.644.62Net Income-$27.78M-$65.73M$3.18B$245.85M7 Day Performance3.52%-4.01%-2.00%-2.61%1 Month Performance35.20%-9.02%-0.44%-2.14%1 Year Performance-13.11%-15.61%16.44%12.98% OncoCyte Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OCXOncoCyte2.4404 of 5 stars$2.65-2.6%$4.42+66.7%-13.7%$47.47M$1.50M0.00120Gap UpSLDBSolid Biosciences4.0798 of 5 stars$3.44+19.4%$15.30+344.8%-42.4%$137.45M$8.09M-1.13100Analyst ForecastAnalyst RevisionNews CoverageGap UpHigh Trading VolumePBYIPuma Biotechnology3.7611 of 5 stars$2.78flat$7.00+151.8%-55.5%$136.47M$243.57M5.79200Upcoming EarningsNews CoverageBMEABiomea Fusion3.3375 of 5 stars$3.76+0.3%$39.36+946.9%-77.4%$136.26MN/A-0.9450Positive NewsCHRSCoherus BioSciences3.6681 of 5 stars$1.17+4.5%$5.38+359.4%-56.9%$135.59M$257.24M-14.63330MCRBSeres Therapeutics3.9958 of 5 stars$0.79+0.4%$5.08+547.1%-23.5%$134.12M$126.33M-3.42330News CoverageTELOTelomir Pharmaceuticals2.2818 of 5 stars$4.47+2.3%N/A-54.8%$133.03MN/A-7.711Analyst ForecastNews CoverageTILInstil Bio2.9407 of 5 stars$20.02-3.9%$114.00+469.4%+88.3%$130.65MN/A-1.73410News CoveragePositive NewsKYTXKyverna Therapeutics1.1479 of 5 stars$3.01+0.3%$25.71+754.3%-89.9%$129.94M$7.03M0.0096TSVT2seventy bio2.1813 of 5 stars$2.45+6.5%$7.20+193.9%-53.2%$126.40M$100.39M-1.32440Analyst ForecastNews CoverageBDTXBlack Diamond Therapeutics3.3805 of 5 stars$2.23-9.3%$15.50+595.1%-53.7%$126.17MN/A-1.6890Short Interest ↓Positive News Related Companies and Tools Related Companies Solid Biosciences Alternatives Puma Biotechnology Alternatives Biomea Fusion Alternatives Coherus BioSciences Alternatives Seres Therapeutics Alternatives Telomir Pharmaceuticals Alternatives Instil Bio Alternatives Kyverna Therapeutics Alternatives 2seventy bio Alternatives Black Diamond Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:OCX) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersWhat is this southern state hiding?The financial press had a field day this week after President Donald Trump and Department of Government Effici...Stansberry Research | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OncoCyte Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share OncoCyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
